Implication of complement system and its regulators in alzheimer's disease

Current Neuropharmacology

Volumn 7, Issue 1, 2009, Pages 1-8

  Kolev, Martin V ^a   Ruseva, Marieta M ^a   Harris, Claire L ^a   Morgan, B Paul ^a   Donev, Rossen M ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

amyloid peptide; Alzheimer's disease; CD59; Complement; Complement regulators; Complement therapeutics; Inflammation; Neurodegeneration

Indexed keywords

ALPHA SYNUCLEIN; ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; ANTIBODY; APOLIPOPROTEIN E; BETA SECRETASE; CASPASE; CD59 ANTIGEN; CEREBROLYSIN; CLASSICAL COMPLEMENT PATHWAY C3 C5 CONVERTASE; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; COMPLEMENT COMPONENT C4 BIDING PEPTIDE; COMPLEMENT COMPONENT C5; COMPLEMENT COMPONENT C5 ANTIBODY; COMPLEMENT COMPONENT C5A; COMPLEMENT COMPONENT C8 ANTIBODY; COMPLEMENT COMPONENT C9; COMPLEMENT INHIBITOR; COMPLEMENT MEMBRANE ATTACK COMPLEX; DECAY ACCELERATING FACTOR; GAMMA SECRETASE; GLYCOSAMINOGLYCAN; LECTIN; MEMBRANE COFACTOR PROTEIN; PEPTIDE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; APOPTOSIS; CELL SURVIVAL; COGNITION; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM; CYTOLYSIS; DISEASE ASSOCIATION; ENZYME ACTIVATION; GENE EXPRESSION; GENE TARGETING; HUMAN; NERVE CELL DEGENERATION; NERVE CELL NECROSIS; NEUROFIBRILLARY TANGLE; NEUROPROTECTION; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REVIEW; SENILE PLAQUE;

EID: 65949124441     PISSN: 1570159X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157015909787602805     Document Type: Review

References (69)

1. Akiyama, H., Barger, S., Barnum, S., Bradt, B., Bauer, J., Cole, G., Cooper, N., Eikelenboom, P., Emmerling, M., Fiebich, B., Finch, C., Frautschy, S., Griffin, W., Hampel, H., Hull, M., Landreth, G., Lue, L., Mrak, R., Mackenzie, I., McGeer, P., O'Banion, M., Pachter, J., Pasinetti, G., Plata-Salaman, C., Rogers, J., Rydel, R., Shen, Y., Streit, W., Strohmeyer, R., Tooyoma, I., Van Muiswinkel, F., Veerhuis, R., Walker, D., Webster, S., Wegrzyniak, B., Wenk, G., Wyss-Coray, T. (2000) Inflammation and Alzheimer's disease. Neurobiol. Aging, 21, 383-421.
2. Akiyama, H., Yamada, T., Kawamata, T., McGeer, P. (1991) Association of amyloid P component with complement proteins in neurologically diseased brain tissue. Brain Res, 548, 349-352.
3. Barnum, S. (1995) Complement biosynthesis in the central nervous system. Crit. Rev. Oral. Biol. Med., 6, 132-146.
4. Bergamaschini, L., Donarini, C., Gobbo, G., Parnetti, L., Gallai, V. (2001) Activation of complement and contact system in Alzheimer's disease. Mech. Ageing Dev., 122, 1971-1983.
5. Bertram, L., McQueen, M., Mullin, K., Blacker, D., Tanzi, R. (2007) Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat. Genet., 39, 17-23.
6. Bjorge, L., Hakulinen, J., Wahlstrom, T., Matre, R., Meri, S. (1997) Complement-regulatory proteins in ovarian malignancies. Int. J. Cancer, 70, 14-25.
7. Bora, N., Kaliappan, S., Jha, P., Xu, Q., Sivasankar, B., Harris, C., Morgan, B., Bora, P. (2007) CD59, a complement regulatory protein, controls choroidal neovascularization in a mouse model of wet-type age-related macular degeneration. J. Immunol., 178, 1783-1790.
8. Bradt, B., Kolb, W., Cooper, N. (1998) Complement-dependent proinflammatory properties of the Alzheimer's disease beta-peptide. J. Exp. Med., 188, 431-438.
9. Brodsky, R., Young, N., Antonioli, E., Risitano, A., Schrezenmeier, H., Schubert, J., Gaya, A., Coyle, L., de Castro, C., Fu, C., Maciejewski, J., Bessler, M., Kroon, H., Rother, R., Hillmen, P. (2008) Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood, 111, 1840-1847.
10. Carrier, M., Menasche, P., Levy, J., Newman, M., Taylor, K., Haverich, A., Chen, J., Shernan, S., Van de Werf, F., van der Laan, M., Todaro, T., Adams, P., Verrier, E. (2006) Inhibition of complement activation by pexelizumab reduces death in patients undergoing combined aortic valve replacement and coronary artery bypass surgery. J. Thorac. Cardiovasc. Surg., 131, 352-356.
11. Carter, C. (2007) Convergence of genes implicated in Alzheimer's disease on the cerebral cholesterol shuttle: APP, cholesterol, lipoproteins, and atherosclerosis. Neurochem. Int., 50, 12-38.
12. Cole, D., Hughes, T., Gasque, P., Morgan, B. (2006) Complement regulator loss on apoptotic neuronal cells causes increased complement activation and promotes both phagocytosis and cell lysis. Mol. Immunol., 43, 1953-1964.
13. Davies, A., Simmons, D., Hale, G., Harrison, R., Tighe, H., Lachmann, P., Waldmann, H. (1989) CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells. J. Exp. Med., 170, 637-654.
14. Degn, S., Thiel, S., Jensenius, J. (2007) New perspectives on mannan-binding lectin-mediated complement activation. Immunobiology, 212, 301-311.
15. Donev, R., Gray, L., Sivasankar, B., Hughes, T., van den Berg, C., Morgan, B. (2008) Modulation of CD59 expression by restrictive silencer factor-derived peptides in cancer immunotherapy for neuroblastoma. Cancer Res., 68, 5979-5987.
16. Donev, R.M., Cole, D.S., Sivasankar, B., Hughes, T.R., Morgan, B.P. (2006) p53 regulates cellular resistance to complement lysis through enhanced expression of CD59. Cancer Res., 66, 2451-2458.
17. Emmerling, M., Watson, M., Raby, C., Spiegel, K. (2000) The role of complement in Alzheimer's disease pathology. Biochim. Biophys. Acta, 1502, 158-171.
18. Gasque, P., Fontaine, M., Morgan, B. (1995) Complement expression in human brain. Biosynthesis of terminal pathway components and regulators in human glial cells and cell lines. J. Immunol., 154, 4726-4733.
19. Gasque, P., Julen, N., Ischenko, A., Picot, C., Mauger, C., Chauzy, C., Ripoche, J., Fontaine, M. (1992) Expression of complement components of the alternative pathway by glioma cell lines. J. Immunol., 149, 1381-1387.
20. Harris, C., Hughes, C., Williams, A., Goodfellow, I., Evans, D., Caterson, B., Morgan, B. (2003) Generation of anti-complement "prodrugs": cleavable reagents for specific delivery of complement regulators to disease sites. J. Biol. Chem., 278, 36068-36076.
21. Harris, C., Williams, A., Linton, S., Morgan, B. (2002) Coupling complement regulators to immunoglobulin domains generates effective anti-complement reagents with extended half-life in vivo. Clin. Exp. Immunol., 129, 198-207.
22. Hila, S., Soane, L., Koski, C. (2001) Sublytic C5b-9-stimulated Schwann cell survival through PI 3-kinase-mediated phosphorylation of BAD. Glia, 36, 58-67.
23. Kaplan, M. (2002) Eculizumab (Alexion). Curr. Opin. Investig. Drugs, 3, 1017-1023.
24. Kishore, U., Gupta, S., Perdikoulis, M., Kojouharova, M., Urban, B., Reid, K. (2003) Modular organization of the carboxyl-terminal, globular head region of human C1q A, B, and C chains. J. Immunol., 171, 812-820.
25. Lanzrein, A., Jobst, K., Thiel, S., Jensenius, J., Sim, R., Perry, V., Sim, E. (1998) Mannan-binding lectin in human serum, cerebrospinal fluid and brain tissue and its role in Alzheimer's disease. Neuroreport, 9, 1491-1495.
26. Lazar, H., Bokesch, P., van Lenta, F., Fitzgerald, C., Emmett, C., Marsh, H.J., Ryan, U. (2004) Soluble human complement receptor 1 limits ischemic damage in cardiac surgery patients at high risk requiring cardiopulmonary bypass. Circulation, 110, II274-279.
27. Lazar, H., Keilani, T., Fitzgerald, C., Shapira, O., Hunter, C., Shemin, R., Marsh, H.J., Ryan, U. (2007) Beneficial effects of complement inhibition with soluble complement receptor 1 (TP10) during cardiac surgery: is there a gender difference? Circulation, 116, I83-88.
28. Lleó, A., Greenberg, S., Growdon, J. (2006) Current pharmacotherapy for Alzheimer's disease. Ann. Rev. Med., 57, 513-533.
29. Longhi, M., Harris, C., Morgan, B., Gallimore, A. (2006) Holding T cells in check--a new role for complement regulators? Trends Immunol., 27, 102-108.
30. Maier, M., Peng, Y., Jiang, L., Seabrook, T., Carroll, M., Lemere, C. (2008) Complement C3 deficiency leads to accelerated amyloid beta plaque deposition and neurodegeneration and modulation of the microglia/ macrophage phenotype in amyloid precursor protein transgenic mice. J. Neurosci., 28, 6333-6341.
31. McGeer, P., McGeer, E. (1995) The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res. Brain Res. Rev., 21, 195-218.
32. McGeer, P., McGeer, E., Yasojima, K. (2000) Alzheimer disease and neuroinflammation. J. Neural. Transm. Suppl., 59, 53-57.
33. Morgan, B., Gasque, P. (1997) Extrahepatic complement biosynthesis: where, when and why? Clin. Exp. Immunol., 107, 1-7.
34. Morgan, B., Harris, C. (2003) Complement therapeutics; history and current progress. Mol. Immunol., 40, 159-170.
35. Osaka, H., Mukherjee, P., Aisen, P., Pasinetti, G. (1999) Complement-derived anaphylatoxin C5a protects against glutamate-mediated neurotoxicity. J. Cell Biochem., 73, 303-311.
36. Pasinetti, G. (1996) Inflammatory mechanisms in neurodegeneration and Alzheimer's disease: the role of the complement system. Neurobiol. Aging, 17, 707-716.
37. Pasinetti, G., Johnson, S., Oda, T., Rozovsky, I., Finch, C. (1994) Clusterin (SGP-2): a multifunctional glycoprotein with regional expression in astrocytes and neurons of the adult rat brain. J. Comp. Neurol., 339, 387-400.
38. Pedersen, E., Frøyland, E., Kvissel, A., Pharo, A., Skålhegg, B., Rootwelt, T., Mollnes, T. (2007) Expression of complement regulators and receptors on human NT2-N neurons--effect of hypoxia and reoxygenation. Mol. Immunol., 44, 2459-2468.
39. Pisalyaput, K., Tenner, A. (2008) Complement component C1q inhibits beta-amyloid- and serum amyloid P-induced neurotoxicity via caspase- and calpain-independent mechanisms. J. Neurochem., 104, 696-707.
40. Prasad, K., Cole, W., Prasad, K. (2002) Risk factors for Alzheimer's disease: role of multiple antioxidants, non-steroidal antiinflammatory and cholinergic agents alone or in combination in prevention and treatment. J. Am. Coll. Nutr., 21, 506-522.
41. Rich, J., Rasmusson, D., Folstein, M., Carson, K., Kawas, C., Brandt, J. (1995) Nonsteroidal anti-inflammatory drugs in Alzheimer's disease. Neurology, 45, 51-55.
42. Rinder, C., Rinder, H., Smith, M., Tracey, J., Fitch, J., Li, L., Rollins, S., Smith, B. (1999) Selective blockade of membrane attack complex formation during simulated extracorporeal circulation inhibits platelet but not leukocyte activation. J. Thorac. Cardiovasc. Surg., 118, 460-466.
43. Rockenstein, E., Mallory, M., Mante, M., Alford, M., Windisch, M., Moessler, H., Masliah, E. (2002) Effects of Cerebrolysin on amyloid-beta deposition in a transgenic model of Alzheimer's disease. J. Neural. Transm. Suppl., 327-336.
44. Rockenstein, E., Torrance, M., Mante, M., Adame, A., Paulino, A., Rose, J., Crews, L., Moessler, H., Masliah, E. (2006) Cerebrolysin decreases amyloid-beta production by regulating amyloid protein precursor maturation in a transgenic model of Alzheimer's disease. J. Neurosci. Res., 83, 1252-1261.
45. Rus, H., Kim, L., Niculescu, F., Shin, M. (1992) Induction of C3 expression in astrocytes is regulated by cytokines and Newcastle disease virus. J. Immunol., 148, 928-933.
46. Rushmere, N.K., Knowlden, J.M., Gee, J.M.W., Harper, M.E., Robertson, J.F., Morgan, B.P., Nicholson, R.I. (2004) Analysis of the level of mRNA expression of the membrane regulators of complement, Cd59, Cd55 and Cd46, in breast, cancer. Int. J. Cancer, 108, 930-936.
47. Rüther, E., Ritter, R., Apecechea, M., Freytag, S., Gmeinbauer, R., Windisch, M. (2000) Sustained improvements in patients with dementia of Alzheimer's type (DAT) 6 months after termination of Cerebrolysin therapy. J. Neural. Transm., 107, 815-829.
48. Tanna, S. (2004) Alzheimer's disease - Opportunities to address pharmaceutical gaps (a background paper). In: Kaplan, W., Laing, R. Eds., Priority Medicines for Europe and the World. World Health Organization, Department of Essential Drugs and Medicines Policy. pp. 3-6.
49. Selkoe, D. (1999) Translating cell biology into therapeutic advances in Alzheimer's disease. Nature, 399, A23-31.
50. Selkoe, D. (2001) Alzheimer's disease results from the cerebral accumulation and cytotoxicity of amyloid beta-protein. J. Alzheimers Dis., 3, 75-80.
51. Silva, C., Rio, M., Cruz, C. (1985) Local immunoglobulin synthesis and blood-brain barrier assessment in subacute sclerosing panencephalitis. Eur. Neurol., 24, 128-133.
52. Smith, G., Smith, R. (2001) Membrane-targeted complement inhibitors. Mol. Immunol., 38, 249-255.
53. Song, H., He, C., Knaak, C., Guthridge, J., Holers, V., Tomlinson, S. (2003) Complement receptor 2-mediated targeting of complement inhibitors to sites of complement activation. J. Clin. Invest., 111, 1875-1885.
54. Thiel, S. (2007) Complement activating soluble pattern recognition molecules with collagen-like regions, mannan-binding lectin, ficolins and associated proteins. Mol. Immunol., 44, 3875-3888.
55. Trouw, L., Nielsen, H., Minthon, L., Londos, E., Landberg, G., Veerhuis, R., Janciauskiene, S., Blom, A. (2008) C4b-binding protein in Alzheimer's disease: binding to Abeta1-42 and to dead cells. Mol. Immunol., 45, 3649-3660.
56. Urbńyi, Z., Forrai, E., Sárvári, M., Likó, I., Illés, J., Pázmány, T. (2005) Glycosaminoglycans inhibit neurodegenerative effects of serum amyloid P component in vitro. Neurochem. Int., 46, 471-477.
57. Vedeler, C., Ulvestad, E., Bjørge, L., Conti, G., Williams, K., Mørk, S., Matre, R. (1994) The expression of CD59 in normal human nervous tissue. Immunology, 82, 542-547.
58. Veerhuis, R., Janssen, I., Hoozemans, J., De Groot, C., Hack, C., Eikelenboom, P. (1998) Complement C1-inhibitor expression in Alzheimer's disease. Acta Neuropathol., 96, 287-296.
59. Vincent, B., Cisse, M., Sunyach, C., Guillot-Sestier, M., Checler, F. (2008) Regulation of betaAPP and PrPc cleavage by alpha-secretase: mechanistic and therapeutic perspectives. Curr. Alzheimer Res., 5, 202-211.
60. Walport, M. (2001) Complement. First of two parts. N. Engl. J. Med., 344, 1058-1066.
61. Webster, S., Rogers, J. (1996) Relative efficacies of amyloid beta peptide (A beta) binding proteins in A beta aggregation. J. Neurosci. Res., 46, 58-66.
62. Weisman, H., Bartow, T., Leppo, M., Marsh, H.J., Carson, G., Concino, M., Boyle, M., Roux, K., Weisfeldt, M., Fearon, D. (1990) Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science, 249, 146-151.
63. Wyss-Coray, T., Yan, F., Lin, A., Lambris, J., Alexander, J., Quigg, R., Masliah, E. (2002) Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice. Proc. Natl. Acad. Sci. USA, 99, 10837-10842.
64. Yang, L., Li, R., Meri, S., Rogers, J., Shen, Y. (2000) Deficiency of complement defense protein CD59 may contribute to neurodegeneration in Alzheimer's disease. J. Neurosci., 20, 7505-7509.
65. Yasojima, K., McGeer, E., McGeer, P. (1999) Complement regulators C1 inhibitor and CD59 do not significantly inhibit complement activation in Alzheimer disease. Brain Res., 833, 297-301.
66. Yasojima, K., Schwab, C., McGeer, E., McGeer, P. (1999) Upregulated production and activation of the complement system in Alzheimer's disease brain. Am. J. Pathol., 154, 927-936.
67. Zhan, S., Veerhuis, R., Kamphorst, W., Eikelenboom, P. (1995) Distribution of beta amyloid associated proteins in plaques in Alzheimer's disease and in the non-demented elderly. Neurodegeneration, 4, 291-297.
68. Zhang, H., Yu, J., Bajwa, E., Morrison, S., Tomlinson, S. (1999) Targeting of functional antibody-CD59 fusion proteins to a cell surface. J. Clin. Invest., 103, 55-61.
69. Zhang, Y., Goodyer, C., LeBlanc, A. (2000) Selective and protracted apoptosis in human primary neurons microinjected with active caspase-3, -6, -7, and -8. J. Neurosci., 20, 8384-8389.